Task 3.2
Generation of bi-specific nanobodies targeting CD8β+/CD69+ activated cytotoxic T-lymphocytes (CTLs)...
Description
This task will be conducted by VUB, VIB together with expertise from Roche, Pfizer and Takeda. Bi-specific constructs will be generated by linking two lowaffinity nanobodies targeting CD8β and CD69 (from Task 3.1) with a genetic spacer into a design ...
General Design
- Type
- Cohort study
- Start/End data collection
- not available
Organisations
Lead organisations
- F. HOFFMANN-LA ROCHE AGSwitzerlandhttps://www.roche.com/
- PFIZER LIMITEDUnited Kingdom of Great Britain and Northern Ireland (the)https://www.pfizer.com/
- TAKEDA DEVELOPMENT CENTRE EUROPE LTDUnited Kingdom of Great Britain and Northern Ireland (the)
- VRIJE UNIVERSITEIT BRUSSELBelgiumhttps://www.vub.be/en/home
Networks
Part of networks...